Unlock LNP potential with enhanced clinical translatability at the 3rd Lipid Nanoparticles Development Summit Europe (24-26 September, Berlin, Germany), the leading dedicated LNP f
2023 is set to be a landmark year for lipid-based delivery technology development and the 2nd Next-Generation Lipid-Based Nanoparticle Delivery Summit re
Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh